Pharmaceuticals

News Hour: India’s largest drugmaker Sun Pharmaceutical Industries said U.S. regulators plan to lift a ban on its Mohali plant in northern India, paving the way for a resumption of exports to the company’s biggest market...

News Hour: Sandoz, a Novartis Division, announced today the three winners of the inaugural Healthcare Access Challenge (Sandoz HACk). The winners, chosen by a panel of judges at the Wired Health 2017 event in London, identified...

News Hour: Sanofi and its vaccines global business unit Sanofi Pasteur announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to develop and commercialize a monoclonal antibody–called MEDI8897–for the prevention of...

News Hour: The U.S. Food and Drug Administration said Pfizer Inc’s process for manufacturing sterile injectable drugs at a plant in McPherson, Kansas was “out of control” and put patients at risk, according to a warning...

News Hour: The U.S. Food and Drug Administration (FDA) has granted priority review to Novartis drug Zykadia as a first-line treatment for some lung cancer patients, the Swiss drugmaker said on Thursday. The priority review covers...

News Hour: CVS Health Corp said its pharmacy chain had removed artificial trans fats, which have been linked to rising rates of heart diseases, from its store-branded food products well ahead of a June 2018 federal...

News Hour: South Korea plans to set up a plant to manufacture a locally developed foot-and-mouth vaccine by 2020 as part of efforts to combat outbreaks of the viral animal disease, the country’s agriculture ministry said...

News Hour: A group of academic researchers has demanded an end to cancer medicines costing more than $100,000 a year and proposed a new model of low-cost drug development that would capitalize on recent advances in...

News Hour: Tetraphase Pharmaceuticals Inc Chief Executive Guy Macdonald said annual sales of the company’s lead experimental antibiotic for serious bacterial infections could climb as high as $700 million if approved. The antibiotic, eravacycline, is being...

News Hour: GlaxoSmithKline and Gilead Sciences will vie for business in treating HIV patients next week when both companies unveil clinical trial results at a medical meeting in Seattle. Most attention is focused on Gilead’s next-generation...